Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abbisko’s CSF-1R Inhibitor Pimicotinib Receives Orphan Drug Designation
Details : ABSK021 (pimicotinib) is a selective CSF-1R inhibitor currently in phase 3 studies for treating inoperable tenosynovial giant cell tumors.
Brand Name : ABSK021
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2024
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor (TGCT).
Brand Name : ABSK021
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2023
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cel...
Brand Name : ABSK021
Molecule Type : Small molecule
Upfront Cash : $70.0 million
December 04, 2023
Lead Product(s) : Pimicotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ABK3376,Furmonertinib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Shanghai Allist Pharmaceuticals
Deal Size : $187.9 million
Deal Type : Licensing Agreement
Shanghai's Abbisko Out-Licenses EGFR Candidate in Potentially Nine-Figure Deal
Details : The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.
Brand Name : ABK3376
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 01, 2023
Lead Product(s) : ABK3376,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Shanghai Allist Pharmaceuticals
Deal Size : $187.9 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Eli Lilly
Deal Size : $258.0 million
Deal Type : Collaboration
Details : Under the terms of the Agreement, Abbisko Therapeutics will be responsible for the further discovery and development of molecules that modulate a novel and challenging drug target using its proprietary R&D platform.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Eli Lilly
Deal Size : $258.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?